Business
SCYNEXIS and Hansoh Pharma Announce Licensing Agreement and Strategic Partnership for Ibrexafungerp in Greater China
Partnership aims to accelerate access to breakthrough therapies in order to combat difficult-to-treat and often drug-resistant fungal infections in Greater
About this update from Scynexis, Inc.
[{"type":"text","content":"\n\nPartnership aims to accelerate access to breakthrough therapies in order to combat difficult-to-treat and often drug-resistant fungal infections in Greater China\n\n\nSCYNEXIS will receive a $10 million upfront payment and will also be eligible to receive development and commercial milestones, plus low double-digit royalties on net product sales \n\n\nIbrexafungerp is a first-in-class, broad-spectrum triterpenoid antifungal agent providing the therapeutic advantages of both IV and oral formulations\n\n\n JERSEY CITY, N.J. & SHANGHAI--(BUSINESS WIRE)--\nSCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, and Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”, 3692:HK), one of the leading biopharmaceutical companies in China, today announced a strategic partnership and license agreement for the development and commercialization of Ibrexafungerp for the Greater China region.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210217005020/en/\nIbrexafungerp is a first-in-class, broad-spectrum triterpenoid antifungal agent providing the therapeutic advantages of both intravenous and oral formulations. It is currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of vaginal yeast infections, and in late-stage development for multiple indications, including life-threatening fungal infections in hospitalized patients.\n\n“We are excited and honored to partner with Hansoh Pharma given their strong experience in the infectious disease space and their exceptional development, manufacturing and commercial capabilities in Greater China.” said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS. “This agreement represents a major step forward for ibrexafungerp in the global market, as resistance to azoles grows and deadly fungal infections such as Candida auris continue to emerge worldwide. This partnership not only provides non-dilutive funding to our Company but also further validates the potential of ibrexafungerp as a global anti-fungal franchise. We continue to seek other opportunities to monetize our global rights and leverage ibrexafungerp’s long-lasting patent exclusivity.”\n\nAifeng Lyu, Ph.D., Presiden...